当前位置: 首页 >> 检索结果
1641. Comparison of Ultrathin- Versus Thin-Strut Stents in Patients With High Bleeding Risk PCI: Results From the COMPARE 60/80 HBR Trial: An Open-Label, Randomized, Controlled Trial.
作者: Pieter C Smits.;Pim A L Tonino.;Sjoerd H Hofma.;Jan-Peter van Kuijk.;Fabrizio Spano.;Amar Al Mafragi.;Ron Pisters.;Jawed Polad.;Kris Bogaerts.;Rohit M Oemrawsingh.;Valeria Paradies.
来源: Circ Cardiovasc Interv. 2024年17卷10期e014042页
No randomized data exist on ultrathin-strut stents in patients at high bleeding risk (HBR) undergoing an abbreviated dual antiplatelet therapy after coronary stenting. The aim of this study was to compare the safety and effectiveness of the ultrathin-strut biodegradable-polymer sirolimus-eluting Supraflex Cruz stent with the thin-strut biodegradable-polymer sirolimus-eluting Ultimaster Tansei stent in patients at HBR with abbreviated dual antiplatelet therapy after stenting.
1642. Relationship Between Renin, Aldosterone, Aldosterone-to-Renin Ratio and Arterial Stiffness and Left Ventricular Mass Index in Young Adults.
作者: Roshan A Ananda.;StellaMay Gwini.;Lawrence J Beilin.;Markus P Schlaich.;Michael Stowasser.;Morag J Young.;Brendan Adler.;Peter J Fuller.;Trevor A Mori.;Jun Yang.
来源: Circulation. 2024年150卷25期2019-2030页
Primary aldosteronism, characterized by renin-independent aldosterone production, is associated with adverse cardiovascular remodeling and outcomes. Elevated cardiovascular risk is observed even in subclinical forms of primary aldosteronism according to studies conducted primarily in middle-aged and elderly populations. This study aimed to assess whether early changes in primary aldosteronism biomarkers during young adulthood are associated with arterial stiffness and left ventricular mass index (LVMI) before the onset of overt disease.
1645. Improved Access to Genetics Care is Needed to Address Health Inequities in ATTRv Amyloidosis.
Improved access to genetics care through eased regulations on genetic counselors and telehealth practices can ameliorate inequities in ATTRv.
1646. Half-Dose Tenecteplase or Primary Percutaneous Coronary Intervention in Older Patients With ST-Elevation Myocardial Infarction: STREAM-2 1-Year Mortality Follow-Up.
作者: Peter R Sinnaeve.;Robert C Welsh.;Alexandra Arias Mendoza.;Arsen D Ristić.;Oleg V Averkov.;Yves Lambert.;José F Kerr Saraiva.;Pablo Sepulveda.;Fernando Rosell-Ortiz.;John K French.;Ljilja B Musić.;Katleen Vandenberghe.;Kris Bogaerts.;Thierry Danays.;Kevin R Bainey.;Paul W Armstrong.;Frans Van de Werf.; .
来源: Circulation. 2024年150卷14期1151-1153页 1648. Coronary Plaque Characteristics in Patients With Chronic Kidney Failure: Impact on Cardiovascular Events and Mortality.
作者: Jonathan Nørtoft Dahl.;Marie B Nielsen.;Laust D Rasmussen.;Per Ivarsen.;Michelle C Williams.;My Hanna Sofia Svensson.;Henrik Birn.;Morten Bøttcher.;Simon Winther.
来源: Circ Cardiovasc Imaging. 2024年17卷10期e017066页
In patients with coronary artery disease, coronary plaques with high-risk features and low-attenuation plaque burden are independent measures associated with major adverse cardiovascular events (MACEs). Patients with chronic kidney failure may have different coronary artery disease characteristics. The aim was to assess the association of coronary plaque characteristics and coronary artery disease extent with MACE and all-cause mortality in patients with chronic kidney failure.
1649. Finerenone Improves Outcomes in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction Irrespective of Age: A Prespecified Analysis of FINEARTS-HF.
作者: Misato Chimura.;Mark C Petrie.;Morten Schou.;Felipe A Martinez.;Alasdair D Henderson.;Brian L Claggett.;Akshay S Desai.;Peter Kolkhof.;Prabhakar Viswanathan.;Andrea Lage.;Carolyn S P Lam.;Michele Senni.;Sanjiv J Shah.;Katja Rohwedder.;Katharina Mueller.;Adriaan A Voors.;Faiez Zannad.;Bertram Pitt.;Muthiah Vaduganathan.;Pardeep S Jhund.;Scott D Solomon.;John J V McMurray.
来源: Circ Heart Fail. 2024年17卷11期e012437页
Finerenone improves outcomes in patients with heart failure and mildly reduced or preserved ejection fraction. It is important to understand the efficacy and safety of finerenone in these patients according to age.
1650. Clinical Use of Bedside Portable Ultra-Low-Field Brain Magnetic Resonance Imaging in Patients on Extracorporeal Membrane Oxygenation: Results From the Multicenter SAFE MRI ECMO Study.
作者: Sung-Min Cho.;Shivalika Khanduja.;Christopher Wilcox.;Kha Dinh.;Jiah Kim.;Jin Kook Kang.;Ifeanyi David Chinedozi.;Zachary Darby.;Matthew Acton.;Hannah Rando.;Jessica Briscoe.;Errol L Bush.;Haris I Sair.;John Pitts.;Lori R Arlinghaus.;Audrey-Carelle N Wandji.;Elena Moreno.;Glenda Torres.;Bindu Akkanti.;Jose Gavito-Higuera.;Steven Keller.;HuiMahn A Choi.;Bo Soo Kim.;Aaron Gusdon.;Glenn J Whitman.; .
来源: Circulation. 2024年150卷24期1955-1965页
Early detection of acute brain injury (ABI) at the bedside is critical in improving survival for patients with extracorporeal membrane oxygenation (ECMO) support. We aimed to examine the safety of ultra-low-field (ULF; 0.064-T) portable magnetic resonance imaging (pMRI) in patients undergoing ECMO and to investigate the ABI frequency and types with ULF-pMRI.
1651. Efficacy and Safety of Finerenone Across the Ejection Fraction Spectrum in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Prespecified Analysis of the FINEARTS-HF Trial.
作者: Kieran F Docherty.;Alasdair D Henderson.;Pardeep S Jhund.;Brian L Claggett.;Akshay S Desai.;Katharina Mueller.;Prabhakar Viswanathan.;Andrea Scalise.;Carolyn S P Lam.;Michele Senni.;Sanjiv J Shah.;Adriaan A Voors.;Faiez Zannad.;Bertram Pitt.;Muthiah Vaduganathan.;Scott D Solomon.;John J V McMurray.
来源: Circulation. 2025年151卷1期45-58页
The effects of treatments for heart failure (HF) may vary among patients according to left ventricular ejection fraction (LVEF). In FINEARTS-HF (Finerenone Trial to Investigate Efficacy and Safety Superior to Placebo in Patients With Heart Failure), the nonsteroidal mineralocorticoid receptor antagonist finerenone reduced the risk of cardiovascular death and total worsening HF events in patients with HF with mildly reduced or preserved ejection fraction. We examined the effect of finerenone according to LVEF in FINEARTS-HF.
1652. Effects of the Nonsteroidal MRA Finerenone With and Without Concomitant SGLT2 Inhibitor Use in Heart Failure.
作者: Muthiah Vaduganathan.;Brian L Claggett.;Ian J Kulac.;Zi Michael Miao.;Akshay S Desai.;Pardeep S Jhund.;Alasdair D Henderson.;Meike Brinker.;James Lay-Flurrie.;Prabhakar Viswanathan.;Markus Florian Scheerer.;Andrea Lage.;Carolyn S P Lam.;Michele Senni.;Sanjiv J Shah.;Adriaan A Voors.;Faiez Zannad.;Bertram Pitt.;John J V McMurray.;Scott D Solomon.
来源: Circulation. 2025年151卷2期149-158页
Patients with heart failure (HF) with mildly reduced or preserved ejection fraction face heightened long-term risks of morbidity and mortality. Sodium-glucose cotransporter-2 inhibitors (SGLT2i) and the nonsteroidal mineralocorticoid receptor antagonist finerenone have both been shown to reduce the risk of cardiovascular events in this population, but the effects of their combined use are not known.
1653. Beyond the Usual Suspects: Myocardial Infarction Triggered by Coronary Vasculitis in a Young Patient With Systemic Lupus Erythematosus.
作者: Maria Jose Santa Ana-Bayona.;Pavel Martinez-Dominguez.;Oscar Perez-Orpinel.;Enrique C Guerra.;Nilda Espinola-Zavaleta.
来源: Circ Cardiovasc Imaging. 2025年18卷2期e017009页 1654. Oral Anticoagulation and Factor VIII Replacement Therapy in Patients With Hemophilia Undergoing Pulsed-Field or Radiofrequency Catheter Ablation for Atrial Fibrillation.
作者: Sanghamitra Mohanty.;Michela Casella.;Paolo Compagnucci.;Prem Geeta Torlapati.;Vincenzo Mirco La Fazia.;Carola Gianni.;Bryan MacDonald.;Angel Quintero Mayedo.;Domenico Giovanni Della Rocca.;John Allison.;Mohamed Bassiouny.;G Joseph Gallinghouse.;John D Burkhardt.;Rodney Horton.;Amin Al-Ahmad.;Luigi Di Biase.;Antonio Dello Russo.;Andrea Natale.
来源: Circ Arrhythm Electrophysiol. 2024年17卷10期e012921页 1655. Intraindividual Comparison of Ultrahigh-Spatial-Resolution Photon-Counting Detector CT and Energy-Integrating Detector CT for Coronary Stenosis Measurement.
作者: Milán Vecsey-Nagy.;Giuseppe Tremamunno.;U Joseph Schoepf.;Chiara Gnasso.;Emese Zsarnóczay.;Nicola Fink.;Dmitrij Kravchenko.;Moritz C Halfmann.;Gerald S Laux.;Jim O'Doherty.;Bálint Szilveszter.;Pál Maurovich-Horvat.;Ismail Mikdat Kabakus.;Pal Spruill Suranyi.;Akos Varga-Szemes.;Tilman Emrich.
来源: Circ Cardiovasc Imaging. 2024年17卷10期e017112页
A recent simulation study proposed that stenosis measurements on coronary computed tomography (CT) angiography are influenced by the improved spatial resolution of photon-counting detector (PCD)-CT. The aim of the current study was to evaluate the impact of ultrahigh-spatial-resolution (UHR) on coronary stenosis measurements and Coronary Artery Disease Reporting and Data System (CAD-RADS) reclassification rates in patients undergoing coronary CT angiography on both PCD-CT and energy-integrating detector (EID)-CT and to compare measurements against quantitative coronary angiography.
1656. Exercise Intolerance and Low Cardiac Filling Pressures in a Woman With a Novel eNOS Mutation.
作者: Sarah McGarrity.;David R Ziehr.;Christina A Austin-Tse.;Marc N Wein.;Raghu R Chivukula.;William M Oldham.
来源: Circ Genom Precis Med. 2024年17卷5期e004741页 1657. Performance and Safety of the Extravascular Implantable Cardioverter Defibrillator Through Long-Term Follow-Up: Final Results From the Pivotal Study.
作者: Paul Friedman.;Francis Murgatroyd.;Lucas V A Boersma.;Jaimie Manlucu.;Bradley P Knight.;Nicolas Clémenty.;Christophe Leclercq.;Anish Amin.;Béla Merkely.;Ulrika Maria Birgersdotter-Green.;Joseph Yat Sun Chan.;Mauro Biffi.;Reinoud Elwin Knops.;Gregory Engel.;Ignacio Muñoz Carvajal.;Laurence M Epstein.;Venkata Sagi.;Jens Brock Johansen.;Maciej Sterliński.;Clemens Steinwender.;Troy Hounshell.;Richard Abben.;Amy E Thompson.;Yan Zhang.;Christopher Wiggenhorn.;Sarah Willey.;Ian Crozier.; .
来源: Circulation. 2025年151卷4期322-332页
Substernal lead placement of the extravascular implantable cardioverter defibrillator (EV ICD) permits both defibrillation at thresholds similar to those seen with transvenous implantable cardioverter defibrillators and effective anti-tachycardia pacing (ATP) while avoiding the vasculature and associated complications. The global Pivotal study has shown the EV ICD system to be safe and effective through 6 months, but long-term experience has yet to be published. Our aim was to report the performance and safety of the EV ICD system throughout the study.
1659. Response by Giacoppo et al to Letter Regarding Article "Coronary Angiography, Intravascular Ultrasound, and Optical Coherence Tomography for Guiding of Percutaneous Coronary Intervention: A Systematic Review and Network Meta-Analysis".
作者: Daniele Giacoppo.;Claudio Laudani.;Giovanni Occhipinti.;Marco Spagnolo.;Antonio Greco.;Carla Rochira.;Federica Agnello.;Davide Landolina.;Maria Sara Mauro.;Simone Finocchiaro.;Placido Maria Mazzone.;Nicola Ammirabile.;Antonino Imbesi.;Carmelo Raffo.;Sergio Buccheri.;Davide Capodanno.
来源: Circulation. 2024年150卷13期e271-e272页 1660. Letter by Zhang Regarding Article, "Coronary Angiography, Intravascular Ultrasound, and Optical Coherence Tomography for Guiding of Percutaneous Coronary Intervention: A Systematic Review and Network Meta-Analysis". |